Medicofarma BiotechWAR:MDB 28 Net Margin % is -1,594.44% as of Mar. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 28/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Medicofarma Biotech ranks worse than 98.54% on this metric.
The historical rank and industry rank for Medicofarma Biotech's Net Margin % or its related term are showing as below:
WAR:MDB'
s Net Margin % Range Over the Past 10 Years
Min: -4727.27 Med: -17.97 Max: 1.1
Current: -4727.27
WAR:MDB's Net Margin % is ranked worse than 98.54% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs WAR:MDB: -4727.27
Medicofarma Biotech (WAR:MDB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Medicofarma Biotech Net Margin % Related Terms
Medicofarma Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Medicofarma Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDB vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicofarma Biotech Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Medicofarma Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicofarma Biotech (WAR:MDB) has a Net Margin % of -1,594.44% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Medicofarma Biotech and its competitors. According to the industry distribution chart, Medicofarma Biotech ranks #942 out of 956 companies in the Drug Manufacturers industry, placing it in the top 98.5%.
Is Medicofarma Biotech's Net Margin % too high?
Medicofarma Biotech's current Net Margin % is -1,594.44%. Based on the distribution chart, Medicofarma Biotech ranks #942 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicofarma Biotech has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicofarma Biotech ranks #942 out of 956 companies for Net Margin %. This places Medicofarma Biotech in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Medicofarma Biotech and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicofarma Biotech's current Net Margin % is -1,594.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.45 — trading 792% above its estimated fair value. The current Net Margin % is -1,594.44%. Medicofarma Biotech's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Net Margin % is -1,594.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?
Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued.
The current stock price of zł0.45 is trading 792% above its estimated GF Value™ of zł0.05.
GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.
Key valuation signals for WAR:MDB:
Net Margin %: -1,594.44%
GF Value™: zł0.05 vs. price of zł0.45 (792% above fair value)
No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
28GF Score
Get the complete analysis for WAR:MDB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDB has been successfully added to your 
